Drug Profile
PASylated interferon variant YNSalpha8 - Weizmann Institute of Science/XL-protein GmbH
Alternative Names: PAS-IFNsuperagonist; PAS-YNSα8; PASylated interferon superagonist; xl-082Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science; XL-protein GmbH
- Class Anti-inflammatories; Interferons
- Mechanism of Action Interferon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany
- 28 Nov 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis in Israel
- 09 Aug 2016 Preclinical development is ongoing in Germany and Israel